Injective Protocol (INJ) is making major strides in the
cryptocurrency market space as it continues to introduce innovative products and strategic collaborations. Following a Dogecoin price spike, INJ, along with
Sui (SUI), also experienced a prominent boost in their prices. With successful
price prediction for 2025 setting sights on all-time highs just as investors keep gaining interest, Injective is setting itself apart in the market. On occasion, it experienced a swift price surge of 10% and continues to gain momentum in the market while projecting a potential bullish run to $100.
In addition, the crypto has unveiled and launched
AUSD, the first native stablecoin on its blockchain. This move connects
Decentralized Finance (DeFi) and
Traditional Finance (TradFi) paving the way for seamless transactions. The blockchain has also started offering
USDM stablecoin as collateral for derivatives. Notably, an upgrade known as
Altaris has been launched on the
Injective Mainnet. Notwithstanding these developments, analysts are raising concerns about the bearish trend on Injective’s price, which at one point experienced a drop of almost 70%. Even with the
Injective 3.0 move aimed at reducing the INJ token supply and transforming INJ into a 'Deflationary Asset', doubts about the rally's sustainability had come up.
Injective has also seen significant interest from major institutions.
21Shares collaborates with Injective Labs to launch the first INJ-linked ETP on Euronext exchanges. Venture capital firms in the US are reportedly shifting their attention away from INJ, but despite some occasional selling pressure, market trends continue to forecast growth for Injective. An important milestone for the coin was $1 billion in on-chain transactions. Expanding its portfolio, it also launched a BUIDL tokenized index for the
BlackRock Fund.
Injective Coin News Analytics from Thu, 22 Feb 2024 08:00:00 GMT to Wed, 13 Nov 2024 12:00:00 GMT -
Rating 8
- Innovation 7
- Rumor -6
